Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial
Use of oral oestrogen-progestin therapy was associated with an increased risk of heart disease and venous thromboembolism, whereas the use of tibolone was associated with an increased risk of ischaemic heart disease, cerebral infarction, and myocardial infarction but not venous thromboembolism. These findings highlight the diverse effects of different hormone combinations and administration methods on the risk of cardiovascular disease.
Authors
- Alkistis Skalkidou (ORCID: https://orcid.org/0000-0002-4935-7532)
- Daniel Schmitz (ORCID: https://orcid.org/0000-0003-4480-891X)
- Weronica E. Ek (ORCID: https://orcid.org/0000-0003-2194-496X)
- Torgny Karlsson (ORCID: https://orcid.org/0000-0001-8095-6149)
- Åsa Johansson (ORCID: https://orcid.org/0000-0002-2915-4498)
- Therese Johansson (ORCID: https://orcid.org/0000-0003-1043-7065)
- Dana Bliuc (ORCID: https://orcid.org/0000-0001-9682-2313)
Institutions
- Uppsala University (SE)
- Garvan Institute of Medical Research (AU)
- Science for Life Laboratory (SE)
- UNSW Sydney (AU)
- St Vincent's Hospital Melbourne (AU)
Publication Details
- Journal
- BMJ
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1136/bmj-2023-078784
- Citations
- 34
- Primary Topic
- Menopause: Health Impacts and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 12.16
Funders
- Hjärt-Lungfonden
- Vetenskapsrådet